Last updated: 11/07/2018 19:49:56
A Phase I, Open-Label, Multiple Dose, Dose Escalation Study of GW786034 in Patients with Solid Tumors
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase I, Open-Label, Multiple Dose, Dose Escalation Study of GW786034 in Patients with Solid Tumors
Trial description: A Phase I, Open-Label, Multiple Dose, Dose Escalation Study of GW786034 in Patients with Solid Tumors
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220-4227.
Steiger M, Grandas F, Jost W, van Camp G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: systematic review . J Neural Transm. 2009;116(2):179-91.
Suttle AB, de Souza P, Arumugham T. Bayesian Methods for Pharmacokinetic/Pharmacodynamic Modeling of Pazopanib-Induced Increases in Blood Pressure and Transaminases. J Clin Pharmacol. 2013;53(4):377-384.
Medical condition
Carcinoma, Renal Cell
Product
pazopanib
Collaborators
Not applicable
Study date(s)
December 2002 to September 2006
Type
Not applicable
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2006-26-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website